<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970397</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-JUV13001</org_study_id>
    <nct_id>NCT01970397</nct_id>
  </id_info>
  <brief_title>JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines</brief_title>
  <official_title>A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of JUVEDERM® Ultra XC Injectable Gel Versus Belotero Balance® for Perioral Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, controlled, multi-center study of the safety and effectiveness of
      JUVEDERM® Ultra XC injectable gel versus Belotero Balance® for perioral lines
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The investigator evaluated the severity of the participant's upper and low lip at Baseline (Pre-treatment) to Month 6 using the 4-point POLSS where None=No lines, Mild=Few, shallow lines, Moderate=Some, moderate lines or Severe=Many, deep lines or crevices. The percentage of participants with at least a 1 Point Improvement is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant Assessed Procedural and Post-Procedural Pain Levels</measure>
    <time_frame>During injection, immediately following injection, 15, 30, and 45 min post-injection</time_frame>
    <description>The participant assessed procedural and post-procedural pain using an 11-point scale where: 0=no pain to 10=worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Global Assessment of Change in Appearance of Perioral Lines</measure>
    <time_frame>Baseline, Days 7, 14, Days 7, 14 after touch-up, Months 1, 3 and 6</time_frame>
    <description>The participant evaluated the change in the appearance of their perioral lines (the lines that radiate outward from the edges of the upper and lower lips) using a 7-point scale where: 1 = Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Patients With Moderate to Severe Perioral Lines</condition>
  <arm_group>
    <arm_group_label>JUVEDERM® Ultra XC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioral lines treated with JUVEDERM® Ultra XC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belotero Balance®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioral Lines treated with Belotero Balance®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVEDERM® Ultra XC</intervention_name>
    <description>Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).</description>
    <arm_group_label>JUVEDERM® Ultra XC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Belotero Balance®</intervention_name>
    <description>Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).</description>
    <arm_group_label>Belotero Balance®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have moderate to severe perioral lines as assessed by the Investigator using the
             4-point POLSS (none, mild, moderate, and severe)

          -  Accept the obligation not to receive any other facial procedures or treatments at any
             time during the study that are not study related

        Exclusion Criteria:

          -  Have lip tattoos, facial hair or scars that would interfere with visualization of the
             lips and perioral area for the effectiveness assessments

          -  Have dentures or any device covering all or part of the upper palate, and/or severe
             malocclusion, dentofacial or maxillofacial deformities, or significant asymmetry of
             the perioral area, as judged by the Treating Investigator

          -  Have a history of skin cancer

          -  Is an active smoker

          -  Has noticeable acne scarring, active inflammation, infection, cancerous or
             precancerous lesion, or unhealed wound in the mouth area

          -  Have had an active oral herpes or cold sore within 12 months

          -  Have undergone oral surgery or other dental procedures (e.g., tooth extraction,
             orthodontia, or implantation) within 30 days prior to enrollment or be planning to
             undergo any of these procedures during the study

          -  Have undergone cosmetic facial or perioral area procedures [e.g., face-lift, or other
             surgeries which may alter the appearance of the perioral area, including tissue
             grafting, or tissue augmentation with silicone, fat, or other permanent fillers] or be
             planning to undergo any of these procedures at any time during the study

          -  Have undergone temporary or semi-permanent facial dermal filler injections (e.g.,
             hyaluronic acid, calcium hydroxylapatite, L-Polylactic acid) in the lower face (below
             the orbital rim) within 24 months

          -  Have received mesotherapy, or resurfacing (laser, photomodulation, intense pulsed
             light, radio frequency, dermabrasion, chemical peel, or other ablative or non-ablative
             procedures) within 6 months prior to entry in the study or be planning to undergo any
             of these procedures at any time during the study other than study related procedures.

          -  Have begun use of any new over-the-counter or prescription, oral or topical,
             antiwrinkle products in the treatment area within 90 days prior to enrollment or be
             planning to begin use of such products at any time during the study. [NOTE: Use of
             sunscreens and continued therapy with some cosmeceuticals (e.g., alpha hydroxyl acids,
             glycolic acids, retinol, or retinoic acids) is allowed if the regimen was established
             ≥ 90 days prior to enrollment]

          -  Have had epilation (e.g. laser hair removal, electrolysis, threading, etc.) in the
             perioral area performed within 3 months

          -  Have received treatment with botulinum toxin of any serotype for any indication in the
             lower face [below the infraorbital rims (IORs)] within 1 year of the baseline visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <results_first_submitted>August 5, 2015</results_first_submitted>
  <results_first_submitted_qc>August 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2015</results_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>JUVEDERM® Ultra XC</title>
          <description>JUVEDERM® Ultra XC injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
        </group>
        <group group_id="P2">
          <title>Belotero Balance®</title>
          <description>Belotero Balance® injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population included all randomized participants who received study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>JUVEDERM® Ultra XC</title>
          <description>JUVEDERM® Ultra XC injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
        </group>
        <group group_id="B2">
          <title>Belotero Balance®</title>
          <description>Belotero Balance® injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="7.5"/>
                    <measurement group_id="B2" value="58.2" spread="9.26"/>
                    <measurement group_id="B3" value="58.2" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS)</title>
        <description>The investigator evaluated the severity of the participant’s upper and low lip at Baseline (Pre-treatment) to Month 6 using the 4-point POLSS where None=No lines, Mild=Few, shallow lines, Moderate=Some, moderate lines or Severe=Many, deep lines or crevices. The percentage of participants with at least a 1 Point Improvement is reported.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Participants from the Intent-to-treat population, all randomized treated participants, with data available for analysis at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>JUVEDERM® Ultra XC</title>
            <description>JUVEDERM® Ultra XC injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
          </group>
          <group group_id="O2">
            <title>Belotero Balance®</title>
            <description>Belotero Balance® injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS)</title>
          <description>The investigator evaluated the severity of the participant’s upper and low lip at Baseline (Pre-treatment) to Month 6 using the 4-point POLSS where None=No lines, Mild=Few, shallow lines, Moderate=Some, moderate lines or Severe=Many, deep lines or crevices. The percentage of participants with at least a 1 Point Improvement is reported.</description>
          <population>Participants from the Intent-to-treat population, all randomized treated participants, with data available for analysis at Month 6.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Assessed Procedural and Post-Procedural Pain Levels</title>
        <description>The participant assessed procedural and post-procedural pain using an 11-point scale where: 0=no pain to 10=worst pain imaginable.</description>
        <time_frame>During injection, immediately following injection, 15, 30, and 45 min post-injection</time_frame>
        <population>Intent-to-treat population included all randomized and treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>JUVEDERM® Ultra XC</title>
            <description>JUVEDERM® Ultra XC injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
          </group>
          <group group_id="O2">
            <title>Belotero Balance®</title>
            <description>Belotero Balance® injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Assessed Procedural and Post-Procedural Pain Levels</title>
          <description>The participant assessed procedural and post-procedural pain using an 11-point scale where: 0=no pain to 10=worst pain imaginable.</description>
          <population>Intent-to-treat population included all randomized and treated participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.4" upper_limit="3.5"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.8" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediately following Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.5" upper_limit="1.1"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes following Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.3" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes following Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes following Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Global Assessment of Change in Appearance of Perioral Lines</title>
        <description>The participant evaluated the change in the appearance of their perioral lines (the lines that radiate outward from the edges of the upper and lower lips) using a 7-point scale where: 1 = Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.</description>
        <time_frame>Baseline, Days 7, 14, Days 7, 14 after touch-up, Months 1, 3 and 6</time_frame>
        <population>Participants from the Intent-to-treat population, all randomized treated participants, with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>JUVEDERM® Ultra XC</title>
            <description>JUVEDERM® Ultra XC injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
          </group>
          <group group_id="O2">
            <title>Belotero Balance®</title>
            <description>Belotero Balance® injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Global Assessment of Change in Appearance of Perioral Lines</title>
          <description>The participant evaluated the change in the appearance of their perioral lines (the lines that radiate outward from the edges of the upper and lower lips) using a 7-point scale where: 1 = Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.</description>
          <population>Participants from the Intent-to-treat population, all randomized treated participants, with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.7" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.9" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 or Touch-up (n=66,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.8" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 after Touch-up (n=30,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.6" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 after Touch-up (n=32,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.6" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=66,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.8" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=68,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.7" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.2" lower_limit="2.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=67,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.7" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population, all randomized treated participants, was used to determine the number of participants at risk for Serious and Non-serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>JUVEDERM® Ultra XC</title>
          <description>JUVEDERM® Ultra XC injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
        </group>
        <group group_id="E2">
          <title>Belotero Balance®</title>
          <description>Belotero Balance® injected into perioral lines (2.0 mLs for initial treatment on Day 1 and 1.0 mL for touch-up treatment 2 weeks later if applicable).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruise</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

